Showing 1 - 3 results of 3 for search 'DeJesus Edwin', query time: 0.03s Refine Results
  1. 1
    A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

    A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice... by McClernon Daniel, Patel Parul, DeJesus Edwin, LaMarca Anthony, Salvato Patricia, Kumar Princy N, Florance Allison, Shaefer Mark S

    Published 2009-04-01
    Get full text
    Article
  2. 2
    Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

    Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT by Ross Lisa L, Liao Qiming, Fischl Margaret A, DeJesus Edwin, Weinberg Winkler G, Smith Kimberly Y, Pakes Gary E, Pappa Keith A, Lancaster C Tracey

    Published 2008-03-01
    Get full text
    Article
  3. 3
    Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

    Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment by Snidow Jerry W, Wakeford John H, Williams Vanessa C, Olliffe Jeffrey F, Rodriguez Allan, DeJesus Edwin, Sension Michael G, Keiser Philip H, Shachoy-Clark Anne D, Fleming Julie W, Pakes Gary E, Hernandez Jaime E

    Published 2005-01-01
    Get full text
    Article

Search Tools: